AR084263A1 - Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) - Google Patents

Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)

Info

Publication number
AR084263A1
AR084263A1 ARP110104656A ARP110104656A AR084263A1 AR 084263 A1 AR084263 A1 AR 084263A1 AR P110104656 A ARP110104656 A AR P110104656A AR P110104656 A ARP110104656 A AR P110104656A AR 084263 A1 AR084263 A1 AR 084263A1
Authority
AR
Argentina
Prior art keywords
dendritic cell
bdca
directed against
antibody directed
membrane protein
Prior art date
Application number
ARP110104656A
Other languages
English (en)
Inventor
Nathalie Fournier
Romuef Christophe De
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44140885&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of AR084263A1 publication Critical patent/AR084263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

Reivindicación 1: Anticuerpo monoclonal o policlonal dirigido contra la proteína BDCA-2 para su utilización en el área de la prevención o del tratamiento de patologías que implican una activación de las células dendríticas plasmocitoides, en donde dichas patologías son tumores hematopoyéticos de fenotipo CD4+, CD56+.
ARP110104656A 2010-12-13 2011-12-13 Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) AR084263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1060428A FR2968561B1 (fr) 2010-12-13 2010-12-13 Utilisation d'un anticorps dirige contre une proteine membranaire

Publications (1)

Publication Number Publication Date
AR084263A1 true AR084263A1 (es) 2013-05-02

Family

ID=44140885

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104656A AR084263A1 (es) 2010-12-13 2011-12-13 Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)

Country Status (7)

Country Link
US (1) US20130315820A1 (es)
EP (3) EP2651978B2 (es)
AR (1) AR084263A1 (es)
DK (1) DK2651978T3 (es)
ES (3) ES2842526T3 (es)
FR (1) FR2968561B1 (es)
WO (1) WO2012080642A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
MX363407B (es) * 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
JP6685225B2 (ja) * 2013-12-16 2020-04-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 形質細胞様樹状細胞の枯渇
BR112016014920A2 (pt) 2013-12-24 2017-12-12 Astellas Pharma Inc novo anticorpo anti-bdca-2 humano
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
US10215758B2 (en) 2015-08-25 2019-02-26 The Board Of Trustees Of The Leland Stanford Junior University Platinum-labeled probes for mass cytometry
FR3045386B1 (fr) * 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
WO2024010118A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 항 bdca-2 항체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1060428A (fr) 1952-07-19 1954-04-01 Perfectionnements aux nez de lances d'incendie et analogues
CA2664137C (en) † 1999-11-15 2012-09-25 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU1785601A (en) 1999-11-24 2001-06-04 Immunex Corporation A human normal counterpart of CD4+ CD56+ cutaneous neoplasm
AU2003282161B2 (en) † 2002-09-13 2010-06-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Cytokine production-inducing antibody
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
NZ554065A (en) * 2004-10-07 2010-12-24 Univ Zuerich Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis
CA2685698A1 (en) † 2007-04-30 2008-11-13 Centocor Ortho Biotech Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
MX363407B (es) † 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
FR3034420A1 (fr) † 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303

Also Published As

Publication number Publication date
ES2636969T3 (es) 2017-10-10
ES2842526T3 (es) 2021-07-14
EP3438129A1 (fr) 2019-02-06
ES2823201T3 (es) 2021-05-06
US20130315820A1 (en) 2013-11-28
FR2968561A1 (fr) 2012-06-15
EP2651978A1 (fr) 2013-10-23
WO2012080642A1 (fr) 2012-06-21
EP2651978B2 (fr) 2022-01-12
EP3438129B1 (fr) 2020-07-22
FR2968561B1 (fr) 2013-08-09
EP3190127A1 (fr) 2017-07-12
EP3190127B1 (fr) 2020-10-07
DK2651978T3 (en) 2017-09-04
EP2651978B1 (fr) 2017-05-10

Similar Documents

Publication Publication Date Title
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
NZ765695A (en) Immune cell organoid co-cultures
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CY1120976T1 (el) Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CU20120095A7 (es) Antagonistas de pcsk9
CU20170023A7 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
TR201910744T4 (tr) Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
EA201400447A1 (ru) АНТИТЕЛА К CD1d

Legal Events

Date Code Title Description
FA Abandonment or withdrawal